Our Pricing

Mounjaro vs Saxenda: Clinical Comparison & UK Bundle Options

Choosing between treatments requires a thorough mounjaro vs saxenda uk comparison based on clinical evidence, dosing convenience, and individual health profiles. At Cured Pharmacy, our UK-registered clinical team provides transparent pricing and expert guidance to help you select the most appropriate weight loss injection, with Mounjaro available from £135.00 and Saxenda from £135.00 subject to prescriber approval.

Mounjaro vs Saxenda: How They Work Differently

Mounjaro contains tirzepatide, the UK's first dual GIP/GLP-1 receptor agonist, activating two distinct hormonal pathways that regulate appetite, glucose metabolism, and energy expenditure [1]. This dual mechanism represents a significant advancement over single-pathway medications.

Saxenda contains liraglutide, a GLP-1 receptor agonist that has been licensed in the UK since 2015 for chronic weight management [2]. While effective, liraglutide activates only the GLP-1 pathway, producing more modest weight reduction compared to dual-agonist treatments.

The mechanistic difference translates to measurably different clinical outcomes. In the SURPASS-2 trial, tirzepatide produced average weight reductions of 22.5% at the 15mg dose over 72 weeks, compared to 9.6% with liraglutide in the SCALE Obesity trial [1][3]. Both medications require prescription assessment by a UK prescriber before dispensing.

Clinical Trial Data: Mounjaro vs Saxenda Efficacy

The SURPASS clinical trial programme demonstrated tirzepatide's superior efficacy across multiple endpoints. In SURPASS-1, participants achieved average weight loss of 15-22.5% depending on dose, with 63% of patients on the highest dose achieving at least 20% body weight reduction [1].

Saxenda's pivotal SCALE trials showed average weight loss of 8-9.2% over 56 weeks, with 33.1% of participants achieving at least 10% weight reduction [3]. While clinically significant, these results are notably lower than tirzepatide outcomes in head-to-head comparisons.

Real-World Effectiveness Considerations

Clinical trial data provides controlled environment results, but real-world effectiveness depends on adherence, lifestyle modifications, and individual metabolic response. Our superintendent pharmacist Tarun Kumar notes that both medications require commitment to dietary changes and regular physical activity to optimise outcomes.

Saxenda's daily injection schedule may affect long-term adherence compared to Mounjaro's once-weekly dosing. UK prescribers consider convenience factors alongside clinical efficacy when recommending treatment, as consistent medication use directly correlates with weight loss success [4].

Dosing Schedules & Administration: Mounjaro vs Saxenda

Mounjaro follows a once-weekly subcutaneous injection schedule, starting at 2.5mg and gradually escalating to a maintenance dose of 5mg, 10mg, or 15mg based on tolerability and response [5]. The KwikPen delivery device requires no dose calculation, delivering pre-set amounts with each injection.

Saxenda requires daily subcutaneous injections, starting at 0.6mg and titrating up to the maintenance dose of 3mg over five weeks [2]. The multi-dose pen allows dose adjustment but requires daily administration, which some patients find less convenient than weekly injections.

Injection technique is identical for both medications: subcutaneous administration into the abdomen, thigh, or upper arm. Our clinical team provides detailed injection training resources with every prescription to ensure proper technique and minimise injection site reactions.

Side Effect Profiles: What UK Patients Experience

Both medications share similar gastrointestinal side effects due to their GLP-1 activity, including nausea, diarrhoea, constipation, and abdominal discomfort [1][2]. These effects typically peak during dose escalation and diminish over 4-8 weeks as the body adapts.

In clinical trials, nausea occurred in approximately 44% of tirzepatide users and 39% of liraglutide users, though severe nausea leading to discontinuation was uncommon (4-6%) [1][3]. Gradual dose titration significantly reduces gastrointestinal tolerability issues.

Serious adverse events are rare but include potential thyroid C-cell tumours (black box warning in the US, though not observed in human studies), pancreatitis, and gallbladder disease [5]. UK prescribers screen for contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 before prescribing either medication.

Managing Common Side Effects

Practical strategies significantly improve tolerability. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated help minimise nausea and gastrointestinal discomfort. Taking the medication with food (for Saxenda) or on a consistent weekly schedule (for Mounjaro) also improves symptom management.

If side effects persist beyond the initial titration period or significantly impact quality of life, contact your prescriber. Dose adjustment or alternative treatment options may be appropriate, and our UK clinical team remains available throughout your treatment journey.

Mounjaro vs Saxenda: UK Pricing & Value Comparison

At Cured Pharmacy, transparent upfront pricing helps UK patients make informed decisions. Mounjaro is available from £135.00 per monthly supply, with final cost determined by your prescribed maintenance dose following clinical assessment.

Saxenda starts from £135.00 per monthly supply at Cured Pharmacy, representing competitive UK pricing for this established GLP-1 treatment. The lower entry price reflects both market positioning and the medication's longer UK availability.

When evaluating value, consider both acquisition cost and clinical outcomes. While Mounjaro carries a higher per-month cost, clinical trials demonstrate superior average weight loss compared to Saxenda [1][3]. Your UK prescriber will discuss cost-effectiveness alongside clinical suitability during your consultation, ensuring the recommended treatment aligns with both your health goals and budget.

Bundle Options & Long-Term Treatment Planning

Weight loss medications typically require 6-12 months of continuous treatment for optimal results. Cured Pharmacy offers flexible prescription options, with most patients receiving 1-3 month supplies depending on prescriber recommendation and treatment response monitoring requirements.

Our online consultation process takes under three minutes, with UK prescribers reviewing your medical history, current medications, and weight loss goals. Approved prescriptions are dispensed from our UK-registered pharmacy with discreet next-day delivery across England, Scotland, Wales, and Northern Ireland.

Which Treatment Is Right for You: Clinical Decision Factors

UK prescribers consider multiple factors when recommending between Mounjaro and Saxenda, including BMI, previous weight loss attempts, comorbidities such as type 2 diabetes, cardiovascular risk factors, and tolerance for injection frequency [5].

Mounjaro may be particularly suitable for patients requiring maximal weight reduction, those with concurrent type 2 diabetes (where dual GIP/GLP-1 activity provides additional glycaemic benefits), or individuals preferring once-weekly administration. The higher efficacy demonstrated in clinical trials makes tirzepatide a strong option for patients with significant weight loss targets [1].

Saxenda remains an effective choice for patients seeking a well-established treatment with extensive real-world safety data, those who prefer daily dosing control, or individuals for whom budget considerations are paramount. The medication's proven track record since 2015 provides reassurance for patients prioritising long-term safety evidence [2][3].

Both medications require commitment to lifestyle modifications including reduced calorie intake and increased physical activity. The MHRA licensing for both treatments specifies use alongside a reduced-calorie diet and increased physical activity, not as standalone interventions [5]. Your UK prescriber will discuss realistic expectations, monitoring requirements, and criteria for treatment continuation during your consultation.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. European Medicines Agency. (2015). Saxenda (liraglutide) Summary of Product Characteristics. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
5. National Institute for Health and Care Excellence. (2023). Tirzepatide for managing overweight and obesity [TA1003]. Retrieved from https://www.nice.org.uk/guidance/ta1003

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to prescribed treatment, dietary modifications, and lifestyle changes.